NYSE:TEVA Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis $36.87 +0.11 (+0.30%) Closing price 09/9/2026 03:59 PM EasternExtended Trading$36.70 -0.18 (-0.48%) As of 09/9/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Teva Pharmaceutical Industries Stock (NYSE:TEVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TEVA alerts:Sign Up Key Stats Today's Range$36.47▼$37.3150-Day Range$30.19▼$38.0252-Week Range$18.21▼$38.37Volume4.00 million shsAverage Volume4.82 million shsMarket Capitalization$42.97 billionP/E Ratio61.45Dividend YieldN/APrice Target$43.10Consensus RatingModerate Buy Company Overview Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders. Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms. The company also develops biosimilar medicines and provides pharmaceutical ingredients to support drug manufacturing. Founded in Jerusalem in 1901, Teva has grown into an international pharmaceutical business serving patients and healthcare providers in markets across North America, Europe and other regions worldwide. Richard Francis has served as Teva’s president and chief executive officer since January 2023.AI Generated. May Contain Errors. Read More Teva Pharmaceutical Industries Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreTEVA MarketRank™: Teva Pharmaceutical Industries scored higher than 83% of companies evaluated by MarketBeat, and ranked 142nd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialTeva Pharmaceutical Industries has a consensus price target of $43.10, representing about 16.9% upside from its current price of $36.87.Amount of Analyst CoverageTeva Pharmaceutical Industries has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Teva Pharmaceutical Industries' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth55.15% Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to grow by 55.15% in the coming year, from $1.94 to $3.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is 61.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is 61.45, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.78.Price to Earnings Growth RatioTeva Pharmaceutical Industries has a PEG Ratio of 4.58. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Teva Pharmaceutical Industries' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.08% of the float of Teva Pharmaceutical Industries has been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 6.63.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently increased by 3.93%, indicating that investor sentiment is decreasing. Dividend0.8 / 5Dividend StrengthN/A Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 33.59% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend. News and Social Media3.7 / 5News Sentiment0.88 News SentimentTeva Pharmaceutical Industries has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Teva Pharmaceutical Industries this week, compared to 9 articles on an average week.Search InterestOnly 8 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows5 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,634,391.00 in company stock.Percentage Held by Insiders0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Teva Pharmaceutical Industries' insider trading history. Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEVA Stock News HeadlinesTeva Announces Launch of Offering of Senior NotesSeptember 7 at 8:12 AM | finance.yahoo.comTeva Announces Launch of Offering of Senior NotesSeptember 7 at 4:11 AM | financialpost.comFMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. | Paradigm Press (Ad)Teva Announces Launch of Offering of Senior NotesSeptember 7 at 3:53 AM | globenewswire.comUBS Group Increases Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $48.00September 6, 2026 | americanbankingnews.comTeva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study - SlideshowSeptember 4, 2026 | seekingalpha.comTeva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?September 4, 2026 | finance.yahoo.comTeva Pharmaceutical Industries Ltd. Upgraded to Investment-Grade by S&P Global RatingsSeptember 4, 2026 | quiverquant.comQSee More Headlines TEVA Stock Analysis - Frequently Asked Questions How have TEVA shares performed this year? Teva Pharmaceutical Industries' stock was trading at $31.21 on January 1st, 2026. Since then, TEVA shares have increased by 18.1% and is now trading at $36.8710. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) released its quarterly earnings results on Tuesday, June, 30th. The company reported $0.02 EPS for the quarter. The company earned $4.14 billion during the quarter. Teva Pharmaceutical Industries had a trailing twelve-month return on equity of 32.64% and a net margin of 4.08%. Read the conference call transcript. Who are Teva Pharmaceutical Industries' major shareholders? Top institutional investors of Teva Pharmaceutical Industries include California State Teachers Retirement System (3.71%), Wellington Management Group LLP (0.66%), Assenagon Asset Management S.A. (0.27%) and National Pension Service (0.21%). Insiders that own company stock include Richard D Francis, Roberto Mignone, Eric A Hughes, Mark Sabag, Tal Zvi Zaks, Eliyahu Sharon Kalif, Christine Fox, Richard Daniell, Amir Weiss, Brian Savage, Matthew Shields, Eric Drape, Placid Jover and Vikki L Conway. View institutional ownership trends. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD) and AT&T (T). Company Calendar Last Earnings6/30/2026Today9/09/2026Morgan Stanley 24th Annual Global Healthcare Conference9/14/2026Barclays 24th Annual Global Financial Services Conference9/14/2026U.S. All Stars Conference9/22/2026Bank of America Global Healthcare Conference9/23/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TEVA's financial health is in the Green zone, according to TradeSmith. TEVA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:TEVA CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees33,950Year Founded1901Price Target and Rating Average Price Target for Teva Pharmaceutical Industries$43.10 High Price Target$48.00 Low Price Target$40.00 Potential Upside/Downside+16.9%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$0.60 Trailing P/E Ratio61.45 Forward P/E Ratio19.01 P/E Growth4.58Net Income$1.41 billion Net Margins4.08% Pretax Margin4.09% Return on Equity32.64% Return on Assets6.34% Debt Debt-to-Equity Ratio1.56 Current Ratio0.88 Quick Ratio0.67 Sales & Book Value Annual Sales$17.26 billion Price / Sales2.49 Cash Flow$3.74 per share Price / Cash Flow9.85 Book Value$6.88 per share Price / Book5.36Miscellaneous Outstanding Shares1,165,300,000Free Float1,159,003,000Market Cap$42.97 billion OptionableOptionable Beta0.87 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:TEVA) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our Partners100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredACTION TAKERS WANTED : Big Elon OpportunityJames Altucher says an FCC filing points to Elon Musk's next major venture, one he believes could dwarf Tesla ...Paradigm Press | SponsoredThe buyers of US debt are vanishing [where the money's going]$9 trillion in US government debt must be rolled over in the next 12 months. Foreign central banks in China, J...Golden Portfolio | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TEVA Stock Alerts